Mary Wilson
Well-known member
Published: 01 June 2023
https://doi.org/10.1093/infdis/jiad195
Adeel A Butt, MBBS, MS, Peng Yan, MS, Obaid S Shaikh, MD, Saad B Omer, MD, MPH, PhD, Florian B Mayr, MD, MS, Victor B Talisa, PhD
Abstract
Background
Clinical benefit of Molnupiravir (MPV) in COVID-19 infected sub-populations is unclear.
Methods
We used a matched cohort study design to determine the rate of hospitalization or death within 30 days of COVID-19 diagnosis among MPV treated and untreated controls. Participants were non-hospitalized, previously uninfected Veterans with a first confirmed SARS-CoV-2 infection between January 1 and August 31, 2022, who were prescribed MPV within 3 days of COVID-19 diagnosis, and matched individuals who were not prescribed MPV.
Results
Among 1,459 matched pairs, the incidence of hospitalization/death was not different among MPV treated vs. untreated controls (48 vs. 44 cases; ARD [95% CI] 0.27 [-0.94,1.49]). No benefit was observed among those >60 or ≤60 years old (ARD 0.27 [-1.25,1.79] vs. -0.29 [-1.22,1.80]), those with specific comorbidities, or by vaccination status. A significant benefit was observed in asymptomatic but not in symptomatic persons (ARD -2.80 [-4.74, -0.87] vs. 1.12 [-0.31,2.55]). Kaplan-Meier curves did not show a difference in proportion of persons who were hospitalized or died among MPV treated compared with untreated controls (logrank P = 0.7).
Conclusion
MPV was not associated with a reduction in hospitalization or death within 30 days of COVID-19 diagnosis. A subgroup of patients presenting without symptoms experienced a benefit.
https://watermark.silverchair.com/j...dpvHEvXVn1VnMpVEZdHJ9D71lI9wKQR5LN_IcfsfWdUmE
https://doi.org/10.1093/infdis/jiad195
Adeel A Butt, MBBS, MS, Peng Yan, MS, Obaid S Shaikh, MD, Saad B Omer, MD, MPH, PhD, Florian B Mayr, MD, MS, Victor B Talisa, PhD
Abstract
Background
Clinical benefit of Molnupiravir (MPV) in COVID-19 infected sub-populations is unclear.
Methods
We used a matched cohort study design to determine the rate of hospitalization or death within 30 days of COVID-19 diagnosis among MPV treated and untreated controls. Participants were non-hospitalized, previously uninfected Veterans with a first confirmed SARS-CoV-2 infection between January 1 and August 31, 2022, who were prescribed MPV within 3 days of COVID-19 diagnosis, and matched individuals who were not prescribed MPV.
Results
Among 1,459 matched pairs, the incidence of hospitalization/death was not different among MPV treated vs. untreated controls (48 vs. 44 cases; ARD [95% CI] 0.27 [-0.94,1.49]). No benefit was observed among those >60 or ≤60 years old (ARD 0.27 [-1.25,1.79] vs. -0.29 [-1.22,1.80]), those with specific comorbidities, or by vaccination status. A significant benefit was observed in asymptomatic but not in symptomatic persons (ARD -2.80 [-4.74, -0.87] vs. 1.12 [-0.31,2.55]). Kaplan-Meier curves did not show a difference in proportion of persons who were hospitalized or died among MPV treated compared with untreated controls (logrank P = 0.7).
Conclusion
MPV was not associated with a reduction in hospitalization or death within 30 days of COVID-19 diagnosis. A subgroup of patients presenting without symptoms experienced a benefit.
https://watermark.silverchair.com/j...dpvHEvXVn1VnMpVEZdHJ9D71lI9wKQR5LN_IcfsfWdUmE